- Home
- DVAX vs NBXG Comparison
DVAX vs NBXG Comparison
Compare DVAX & NBXG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- NBXG
- Stock Information
- Founded
- DVAX 1996
- NBXG 2021
- Country
- DVAX United States
- NBXG United States
- Employees
- DVAX N/A
- NBXG N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- NBXG Trusts Except Educational Religious and Charitable
- Sector
- DVAX Health Care
- NBXG Finance
- Exchange
- DVAX Nasdaq
- NBXG Nasdaq
- Market Cap
- DVAX 1.2B
- NBXG 1.1B
- IPO Year
- DVAX 2004
- NBXG N/A
- Fundamental
- Price
- DVAX $10.15
- NBXG $15.37
- Analyst Decision
- DVAX Buy
- NBXG
- Analyst Count
- DVAX 4
- NBXG 0
- Target Price
- DVAX $26.50
- NBXG N/A
- AVG Volume (30 Days)
- DVAX 1.7M
- NBXG 243.7K
- Earning Date
- DVAX 11-06-2025
- NBXG 01-01-0001
- Dividend Yield
- DVAX N/A
- NBXG 10.25%
- EPS Growth
- DVAX N/A
- NBXG N/A
- EPS
- DVAX N/A
- NBXG N/A
- Revenue
- DVAX $316,268,000.00
- NBXG N/A
- Revenue This Year
- DVAX $23.23
- NBXG N/A
- Revenue Next Year
- DVAX $16.57
- NBXG N/A
- P/E Ratio
- DVAX N/A
- NBXG N/A
- Revenue Growth
- DVAX 26.66
- NBXG N/A
- 52 Week Low
- DVAX $9.20
- NBXG $9.31
- 52 Week High
- DVAX $14.63
- NBXG $12.23
- Technical
- Relative Strength Index (RSI)
- DVAX 52.11
- NBXG 61.02
- Support Level
- DVAX $9.95
- NBXG $15.20
- Resistance Level
- DVAX $10.35
- NBXG $15.61
- Average True Range (ATR)
- DVAX 0.29
- NBXG 0.17
- MACD
- DVAX 0.08
- NBXG 0.00
- Stochastic Oscillator
- DVAX 75.00
- NBXG 55.30
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in "NextGen Companies".